Pulmonary mucormycosis is a rare but fatal condition that frequently occurs in immunocompromised patients. Correct diagnosis and rapid start of preferred antifungal treatment need clinical suspicion. Patient's symptoms may be confluent with other conditions such as bacterial and other fungal infections. We present a case of pulmonary mucormycosis in a patient with end stage renal disease successfully treated with a long course of amphotericin B deoxycholate (AmB) and upper lobectomy of the left lung despite of low pulmonary capacity.
INTRODUCTION
Mucormycosis, previously termed as zygomycosis, is a devastating life threatening infection caused by the ubiquitous filamentous fungi of the Mucorales order of the class of Zygomycetes with an often unfavorable outcome (1) (2) (3) . Pulmonary mucormycosis is manifested in immunocompromised or diabetic patients by cavitation on chest radiograph in 40% of patients (4) . Reports show that the lungs are the leading site of invasive fungal infection in solid organ transplant recipients (5) .
The major principles of treatment of mucormycosis are based on antifungals and excision of infected tissue (2) . We report a case of pulmonary mucormycosis in a renal transplant recipient with a subacute presentation in a three-month period without invasion to the chest wall that underwent an upper lobe lobectomy in the left lung.
CASE SUMMARIES
A 40-year-old male with end stage renal disease and kidney transplantation presented with progressive dyspnea, orthopnea and paroxysmal nocturnal dyspnea four months ago. He also complained of intermittent fever and chills. Past medical history was remarkable for renal failure followed by kidney transplantation 20 years ago. in stable patients that need to switch to an oral antifungal (1, 8) . Adding echinocandins to AmB for at least two weeks may potentially benefit the management of mucormycosis (9), and we did just that.
Despite aggressive surgical and antifungal therapy, the mortality rate of mucormycosis is very high and is equal or more than 40% (2); in pulmonary mucormycosis the mortality rate may increase to greater than 80% in 12 months. Guidelines from the American College of Chest
Physicians for pulmonary surgery state that patients with reduced FEV1 less than 1.5 L may not tolerate lobectomy
and that cardiopulmonary exercise test should be considered (10). Our patient was successfully treated with lobectomy and medical therapy with preservation of pulmonary function.
When surgery is combined with AmB, the patient outcome will be improved (2, 10, 11) . In selected cases of pulmonary mucormycosis refractory to AmB therapy, aggressive surgical debridement combined with antifungal therapy should be considered.
